Key result
Pfizer-BioNTech COVID-19 vaccine booster doses in adolescents aged 12-17 years resulted in primarily mild to moderate reactions, with 91.6% of VAERS reports classified as nonserious.
Why the study?
Is the Pfizer-BioNTech COVID-19 vaccine booster dose safe in adolescents aged 12-17 years?
Observational (n=3,418)
Is the Pfizer-BioNTech COVID-19 vaccine booster dose safe in adolescents aged 12-17 years?
The Pfizer-BioNTech COVID-19 vaccine booster dose in adolescents aged 12-17 years is associated primarily with mild to moderate expected reactions, with serious adverse events being rare.
Answers are grounded in this paper and cite their sources.
Reassures on mostly mild adolescent booster reactions; leaves open rare event confirmation via active surveillance.
During this period, receipt of 3,418 Pfizer-BioNTech booster doses were reported to v-safe for adolescents. Reactions were reported to v-safe with equal or slightly higher frequency after receipt of a booster dose than after dose 2, were primarily mild to moderate in severity, and were most frequently reported the day after vaccination. VAERS received 914 reports of adverse events after Pfizer-BioNTech booster dose vaccination of adolescents; 837 (91.6%) were nonserious and 77 (8.4%) were serious. Health care providers, parents, and adolescents should be advised that local and systemic reactions are expected among adolescents after homologous Pfizer-BioNTech booster vaccination, and that serious adverse events are rare.
No takes yet. Share an insight, caveat, or question.
Hause et al. (2022) conducted an observational in COVID-19 vaccination (n=3,418). Pfizer-BioNTech COVID-19 vaccine booster dose vs. dose 2 was evaluated on Adverse events reported to VAERS and v-safe. Pfizer-BioNTech COVID-19 vaccine booster doses in adolescents aged 12-17 years resulted in primarily mild to moderate reactions, with 91.6% of VAERS reports classified as nonserious.
Synapse has enriched 10 related papers. Consider them for comparative context: